Retinal cases & brief reports · 2026
USE OF SUPRACHOROIDAL TRIAMCINOLONE ACETONIDE IN PEDIATRIC UVEITIS.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hanson Justin, Moussa Kareem, Yamamoto Marcus, Hou Kirk, Pillar Shani, Fung Simon, Chen Judy L, Liao Albert, Fayad Mona, Tsui Irena, Tsui Edmund
Аннотация
PURPOSE: To evaluate the off-label use and safety of suprachoroidal triamcinolone acetonide (SCS-TA) for pediatric uveitic macular edema, retinal vasculitis, and perioperative control of inflammation.
METHODS: Medical records of pediatric patients who received SCS-TA were reviewed. Primary outcomes were visual acuity, intraocular pressure (IOP), and central subfield thickness (CST).
RESULTS: In this retrospective cohort study of eight pediatric patients (10 eyes), median age was 14 years (7‒17 years), and median follow-up duration was 10.5 months (range 6‒22 months). Seven of 10 eyes (70.0%) showed stable or improving visual acuity after SCS-TA injection. Median improvement in visual acuity was 1 line (range 0‒6 lines). Four of 10 eyes had a history of steroid-related IOP elevation due to other agents. One of 10 eyes (10.0%) had a clinically significant increase in IOP (IOP ≥ 21 mmHg and ≥10 mmHg IOP increase from baseline) after SCS-TA injection. Intraocular pressure was controlled only requiring topical drops and did not require surgical intervention. One of 10 phakic eyes (10%) developed a cataract during follow-up. In eyes that received SCS-TA for uveitic macular edema, median improvement in CST was 72 µ m (55‒352 µ m) at last follow-up. There was improvement in retinal vasculitis after injection and no recurrence of uveitis or uveitic macular edema in those receiving SCS-TA before surgery.
CONCLUSION: Suprachoroidal triamcinolone acetonide injection demonstrated an adequate safety profile for pediatric patients with favorable IOP outcomes and limited adverse effects. SCS-TA may be considered for treatment of pediatric uveitic macular edema, retinal vasculitis, and perioperative control of inflammation in children with uveitis undergoing cataract/glaucoma surgery.
METHODS: Medical records of pediatric patients who received SCS-TA were reviewed. Primary outcomes were visual acuity, intraocular pressure (IOP), and central subfield thickness (CST).
RESULTS: In this retrospective cohort study of eight pediatric patients (10 eyes), median age was 14 years (7‒17 years), and median follow-up duration was 10.5 months (range 6‒22 months). Seven of 10 eyes (70.0%) showed stable or improving visual acuity after SCS-TA injection. Median improvement in visual acuity was 1 line (range 0‒6 lines). Four of 10 eyes had a history of steroid-related IOP elevation due to other agents. One of 10 eyes (10.0%) had a clinically significant increase in IOP (IOP ≥ 21 mmHg and ≥10 mmHg IOP increase from baseline) after SCS-TA injection. Intraocular pressure was controlled only requiring topical drops and did not require surgical intervention. One of 10 phakic eyes (10%) developed a cataract during follow-up. In eyes that received SCS-TA for uveitic macular edema, median improvement in CST was 72 µ m (55‒352 µ m) at last follow-up. There was improvement in retinal vasculitis after injection and no recurrence of uveitis or uveitic macular edema in those receiving SCS-TA before surgery.
CONCLUSION: Suprachoroidal triamcinolone acetonide injection demonstrated an adequate safety profile for pediatric patients with favorable IOP outcomes and limited adverse effects. SCS-TA may be considered for treatment of pediatric uveitic macular edema, retinal vasculitis, and perioperative control of inflammation in children with uveitis undergoing cataract/glaucoma surgery.